Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral targeted therapy medication used... 70 KB (6,513 words) - 09:10, 7 May 2024 |
Chronic myelogenous leukemia (section Imatinib) action as a tyrosine kinase, targeted therapies (the first of which was imatinib) that specifically inhibit the activity of the BCR-ABL protein have been... 33 KB (3,797 words) - 16:45, 29 April 2024 |
kinase. Before the 2001 U.S. Food and Drug Administration (FDA) approval of imatinib, no drugs were available to alter the natural progression of CML. Only... 55 KB (6,383 words) - 03:23, 5 December 2023 |
the years. However, French scientists treating leukemia patients with imatinib, a drug used in treating cancer, noted an unexpected side effect: some... 16 KB (1,846 words) - 13:54, 10 April 2024 |
Tyrosine kinase (section GIST and Imatinib) step for the development of cancer. Therefore, kinase inhibitors, such as imatinib and osimertinib, are often effective cancer treatments. Most tyrosine kinases... 43 KB (5,251 words) - 14:08, 17 January 2024 |
anion, the spelling used is sometimes mesilate (as in imatinib mesilate, the mesylate salt of imatinib). Mesylate esters are a group of organic compounds... 4 KB (373 words) - 22:32, 16 February 2024 |
well as in accelerated and chronic phase CML that has not responded to imatinib. It is taken by mouth. Common side effects may include low platelets, low... 19 KB (1,667 words) - 23:27, 9 March 2024 |
exon 17 are responsible for resistance to targeted therapy drugs like imatinib mesylate, a tyrosine kinase inhibitor. KIT-p.D419del (exon 8) — A subset... 42 KB (4,411 words) - 06:24, 6 May 2024 |